endo-BCN-O-PNB is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.

DK1-04e serves as a prodrug for the potent SIRT5 inhibitor DK1-04 (IC50 = 340 nM), demonstrating significant anti-tumor activity in breast cancer models. The compound effectively suppresses mammary tumor progression in both MMTV-PyMT transgenic mice and human xenograft models, with cellular studies confirming SIRT5 inhibition disrupts cancer cell proliferation and transformation.

Lirafugratinib (RLY-4008) is a highly selective irreversible inhibitor of FGFR2 with IC50 of 3 nM. Lirafugratinib shows substantial selectivity over FGFR1 (~250-fold) and FGFR4 (~5,000-fold) in vitro, causes tumor regression in multiple FGFR2-altered human xenograft models.

TNG462 is a potent and selective MTA-cooperative PRMT5 inhibitor. TNG462 has a PRMT5-MTA Ki < 300 fM, HAP1 MTAP-null cellular SDMA IC50 of 800 pM and viability GI50 of 4 nM, an average 45-fold selectivity against MTAP WT cells.

PZL-A is a first-in-class activator of mtDNA synthesis that is capable of restoring function to the most common mutant variants of POLγ. PZL-A binds to an allosteric site at the interface between the catalytic POLγA subunit and the proximal POLγB subunit, which is unaffected by nearly all disease-causing mutations.

GNE-049 (GNE049) is a potent, selective, orally available inhibitor of CBP/p300 bromodomain with biochemical IC50 of 1.1/2.3 nM, respectively.

Pregnenolone-d4-1 (3β-Hydroxy-5-pregnen-20-one-d4-1) is the deuterium labeled Pregnenolone. Pregnenolone (3β-Hydroxy-5-pregnen-20-one) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication. Pregnenolone is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels.

Eptinezumab is a humanized monoclonal antibody. Eptinezumab binds to calcitonin gene-related peptide (CGRP) and blocks its interaction with the receptor. Eptinezumab is used for the prevention of migraine in adults.

Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC).

Sutimlimab, a first-in-class complement protein component 1, s subcomponent (C1s) inhibitor, can be used for the research of cold agglutinin disease. C1s is a serine protease which cleaves C4 and C2 to form the C3 convertase.

Compound B9 is a bioactive compound.

Compound B4is a bioactive compound.

Compound 2926 is a bioactive compound.

XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP).

Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab has an anti-tumor activity.

Alsevalimab is a human monoclonal antibody against B7-H4.

Omburtamab is an anti-CD276 (also known as B7-H3) monoclonal antibody, CD276 is a B7/CD28 immunoglobulin superfamily member expressed among solid human tumours. Omburtamab can bind tumor tissues and be used in various cancers research.

Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators.